Last updated: July 6, 2023
Sponsor: Methodist Health System
Overall Status: Active - Enrolling
Phase
N/A
Condition
Liver Disease
Treatment
Dermabond
Clinical Study ID
NCT05278013
067.IMD.2020.D
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Inpatients at Methodist Dallas Medical Center (MDMC) ≥18 years of age with ascitesrequiring therapeutic paracentesis performed by the procedure team at the bedside.
Exclusion
Exclusion Criteria:
- Paracentesis procedures performed in the interventional radiology department or byphysicians outside of the procedure team.
- Patients who undergo a liver transplant surgery or other abdominal surgeries within 48hours from the paracentesis procedure.
- Patients that undergo paracentesis using a device or kit other than the 18 gaugeSafe-T-Centesis kit
Study Design
Total Participants: 134
Treatment Group(s): 1
Primary Treatment: Dermabond
Phase:
Study Start date:
January 13, 2022
Estimated Completion Date:
January 13, 2024
Study Description
Connect with a study center
Methodist Dallas Medical Center Pharmacy
Dallas, Texas 75203
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.